FOXG1 and cancer: Like with FKH2 (described above), PMR1 deletion-enhancement points to multiple human homologs that are both implicated in the cancer literature to promote cancer when underexpressed, yet are also UES in the pharmacogenomics data, suggesting a potentially clinically useful synthetic lethal vulnerability.